No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS

• Published in: PloS one Vol. 4; no. 8; p. e6489
• Main Authors: Gill, Alan, Kidd, Joshua, Vieira, Fernando, Thompson, Kenneth, Perrin, Steven
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 03.08.2009; Public Library of Science (PLoS)
• Subjects: Age; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - drug therapy; Amyotrophic Lateral Sclerosis - genetics; Analysis; Animal diseases; Animal models; Animals; Body Weight; Carbonates; Clinical trials; Copy number; Disease; Disease control; Disease Models, Animal; Dosage; Drug dosages; Effectiveness; Female; Genetic aspects; Hazards; Humans; Laboratory animals; Lithium; Lithium carbonate; Lithium Carbonate - administration & dosage; Lithium Carbonate - therapeutic use; Lithium ions; Male; Medical research; Medical screening; Mice; Mutation; Nervous system diseases; Neurological Disorders; Neurological Disorders/Movement Disorders; Neurological Disorders/Neuromuscular Diseases; Neurological Disorders/Neuropharmacology; Neurological Disorders/Spinal Disorders; Neuroscience; Neuroscience/Motor Systems; Pharmacology; Pharmacology/Drug Development; Phosphorylation; Proportional Hazards Models; Severity of Illness Index; Survival; Survival Analysis; Therapeutics; Therapy; United States > US; Massachusetts

In any animal model of human disease a positive control therapy that demonstrates efficacy in both the animal model and the human disease can validate the application of that animal model to the discovery of new therapeutics. Such a therapy has recently been reported by Fornai et al. using chronic l...